- Home
- CRDL vs CODA Comparison
CRDL vs CODA Comparison
Compare CRDL & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- CODA
- Stock Information
- Founded
- CRDL 2017
- CODA 1994
- Country
- CRDL Canada
- CODA United States
- Employees
- CRDL N/A
- CODA N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- CODA Industrial Machinery/Components
- Sector
- CRDL Health Care
- CODA Industrials
- Exchange
- CRDL Nasdaq
- CODA Nasdaq
- Market Cap
- CRDL 90.4M
- CODA 88.8M
- IPO Year
- CRDL N/A
- CODA N/A
- Fundamental
- Price
- CRDL $1.07
- CODA $9.02
- Analyst Decision
- CRDL Strong Buy
- CODA Strong Buy
- Analyst Count
- CRDL 2
- CODA 1
- Target Price
- CRDL $9.00
- CODA $11.00
- AVG Volume (30 Days)
- CRDL 781.9K
- CODA 88.9K
- Earning Date
- CRDL 11-13-2025
- CODA 09-15-2025
- Dividend Yield
- CRDL N/A
- CODA N/A
- EPS Growth
- CRDL N/A
- CODA 15.09
- EPS
- CRDL N/A
- CODA 0.30
- Revenue
- CRDL N/A
- CODA $24,347,217.00
- Revenue This Year
- CRDL N/A
- CODA $30.82
- Revenue Next Year
- CRDL N/A
- CODA $20.84
- P/E Ratio
- CRDL N/A
- CODA $28.40
- Revenue Growth
- CRDL N/A
- CODA 29.34
- 52 Week Low
- CRDL $0.77
- CODA $5.76
- 52 Week High
- CRDL $2.24
- CODA $9.89
- Technical
- Relative Strength Index (RSI)
- CRDL 44.73
- CODA 63.35
- Support Level
- CRDL $1.04
- CODA $7.85
- Resistance Level
- CRDL $1.16
- CODA $8.88
- Average True Range (ATR)
- CRDL 0.06
- CODA 0.40
- MACD
- CRDL 0.00
- CODA 0.05
- Stochastic Oscillator
- CRDL 20.83
- CODA 94.87
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.